CYP2U1: A Popular Drug Target (G113612)

Target Name: CYP2U1

NCBI ID: G113612

CYP2U1

CYP2U1: A Popular Drug Target

CYP2U1, also known as CYP2U1A, is a cytochrome P450 enzyme that is primarily expressed in the liver and other organs. It is a key metabolizer of a wide variety of drugs, including many statins, antidepressants, and opioids. As a result, CYP2U1 has become a popular drug target for researchers looking for new treatments for various diseases.

One of the main reasons for the popularity of CYP2U1 as a drug target is its high degree of expression. The human body produces about 90% of the enzyme CYP2U1, which means that it is always available in the body and can be easily targeted by drugs. Additionally, CYP2U1 is a good candidate for drug discovery because it has a well-established gene structure and a known mechanism of action.

Another reason why CYP2U1 is a promising drug target is its role in many diseases. Many drugs that are used to treat various diseases are metabolized by CYP2U1, and changes in the levels of this enzyme can affect the efficacy and side effects of these drugs. For example, in patients taking statins to treat high cholesterol, changes in CYP2U1 activity can affect the levels of the statin in the body and the effectiveness of the treatment.

In addition to its role in drug metabolism, CYP2U1 is also a potential biomarker for certain diseases. Because it is expressed in many different tissues and cells in the body, changes in CYP2U1 activity can be an indicator of certain diseases. For example, CYP2U1 levels have been used as a biomarker for cancer, and changes in these levels have been associated with the development and progression of certain types of cancer.

Another potential application of CYP2U1 as a drug target is its role in the treatment of addiction. The CYP2U1 enzyme is involved in the metabolism of many drugs that are commonly used to treat addiction, including many opioids and benzodiazepines. Therefore, changes in CYP2U1 activity can affect the efficacy of these drugs and the risk of abuse. As a result, CYP2U1 has become a target for researchers studying the use of drugs to treat addiction.

In conclusion, CYP2U1 is a promising drug target due to its high degree of expression, its role in many diseases, and its potential as a biomarker. As research continues to advance, the potential applications of CYP2U1 as a drug target will likely expand.

Protein Name: Cytochrome P450 Family 2 Subfamily U Member 1

Functions: A cytochrome P450 monooxygenase involved in the metabolism of arachidonic acid and its conjugates (PubMed:14660610, PubMed:24563460). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:14660610, PubMed:24563460). Acts as an omega and omega-1 hydroxylase for arachidonic acid and possibly for other long chain fatty acids. May modulate the arachidonic acid signaling pathway and play a role in other fatty acid signaling processes (PubMed:14660610, PubMed:24563460). May down-regulate the biological activities of N-arachidonoyl-serotonin, an endocannabinoid that has anti-nociceptive effects through inhibition of fatty acid amide hydrolase FAAH, TRPV1 receptor and T-type calcium channels. Catalyzes C-2 oxidation of the indole ring of N-arachidonoyl-serotonin forming a less active product 2-oxo-N-arachidonoyl-serotonin (PubMed:24563460)

The "CYP2U1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2U1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets